ReviewChinese herbal medicines2026
Advanced applications of synthetic biology technology in biosynthesis of bioactive compounds from medicinal plants.
Review in Chinese herbal medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Functional Engineering of Bioactive Peptides: Chemical Modifications and Synthetic Biology Approaches.International journal of molecular sciences · 2026Review
- Development of Bacillus subtilis cell factories for nutraceuticals production.World journal of microbiology & biotechnology · 2026Review
- Advances in Sustainable Lutein Production: Sources, Technologies, and Functional Applications.Foods (Basel, Switzerland) · 2026Review
- Editorial: Bioactive natural products for health: isolation, structural elucidation, biological evaluation, structure-activity relationship, and mechanism, volume II.Frontiers in chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medicinal plants serve as valuable sources of bioactive compounds with critical applications across pharmaceutical, agricultural, and industrial sectors. Compared to chemical synthesis and plant extraction, synthetic biology offers a green, efficient, and sustainable alternative for producing bioactive compounds, which represents a state of art technology. However, this technology still faces several challenges, including overly long metabolic pathways, inadequate catalytic efficiency of key enzymes in the pathway, and incompatibility between gene elements and host cells, leading to low yields of target bioactive compounds. The development and application of regulatory tools in synthetic biology hold great promise for overcoming these obstacles. This review first summarizes the classification and biosynthesis of bioactive compounds based on structural types. Subsequently, recent advancements are outlined in regulation tools and their application in the heterologous production of bioactive compounds. This review aims to establish a foundation for the efficient production of bioactive compounds based on microbial cell factories. This not only has significant practical implications for reducing the resource consumption and environmental impact of traditional production methods, but also highlights the central role of synthetic biology in promoting the sustainable production of bioactive compounds derived from medicinal plants.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.